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Aims Unrecognized myocardial infarctions (UMIs) have been described in 19–30% of the general population using late gado-
linium enhancement (LGE) on cardiac magnetic resonance. However, these studies have focused on an unselected co-
hort including those with known cardiovascular disease (CVD). The aim of the current study was to ascertain the
prevalence of UMIs in a non-high-risk population using magnetic resonance imaging (MRI).
Methods
and results
A total of 5000 volunteers aged .40 years with no history of CVD and a 10-year risk of CVD of ,20%, as assessed by
the ATP-III risk score, were recruited to the Tayside Screening for Cardiac Events study. Those with a B-type natriuretic
peptide (BNP) level greater than their gender-specific median were invited for a whole-body MR angiogram and cardiac
MR including LGE assessment. LGE was classed as absent, UMI, or non-specific. A total of 1529 volunteers completed
the imaging study; of these, 53 (3.6%) were excluded because of either missing data or inadequate LGE image quality.
Ten of the remaining 1476 (0.67%) displayed LGE. Of these, three (0.2%) were consistent with UMI, whereas seven
were non-specific occurring in the mid-myocardium (n ¼ 4), epicardium (n ¼ 1), or right ventricular insertion points
(n ¼ 2). Those with UMI had a significantly higher BNP [median 116 (range 31–133) vs. 22.6 (5–175) pg/mL,
P ¼ 0.015], lower ejection fraction [54.6 (36–62) vs. 68.9 (38–89)%, P ¼ 0.007], and larger end-systolic volume
[36.3 (27–61) vs. 21.7 (5–65) mL/m2, P ¼ 0.014]. Those with non-specific LGE had lower diastolic blood pressure
[68 (54–70) vs. 72 (46–98) mmHg, P ¼ 0.013] but no differences in their cardiac function.
Conclusion Despite previous reports describing high prevalence of UMI in older populations, in a predominantly middle-aged co-
hort, those who are of intermediate or low cardiovascular risk have a very low risk of having an unrecognized myocar-
dial infarct.
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Introduction
Unrecognized myocardial infarcts (UMIs) have been described in
19–44% of the general population, with prevalence increasing by
10% per decade and their presence associated with a similar or
worse prognosis than recognized myocardial infarcts (RMIs).1,2
The majority of population-based studies have focused on the use
of electrocardiogram (ECG) for the detection of UMI; however,
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not all infarcts result in pathological Q waves.3 Late gadolinium en-
hancement (LGE) on cardiac magnetic resonance (CMR) imaging
has become the clinical gold standard for the detection of myocar-
dial scarring, with a significantly higher detection rate of UMIs than
using ECG alone.4 These UMIs detected on CMR have significant
clinical implications, with those with evidence of myocardial scarring
in the absence of clinically apparent prior infarct more likely to have
chest pain and poorer left ventricular (LV) function and suffer from a
greater number of major adverse cardiovascular events.4,5
Earlier studies have described the prevalence of UMIs in elderly
populations at high risk of cardiovascular disease (CVD). These
studies, by including those with known CVD, have thereby conflated
the prevalence of UMIs in the general population.4,6 The prevalence
of UMIs in a population without prior cardiovascular events and
who are not at high risk has not been previously undertaken. Fur-
thermore, a prior study of 75-year-olds has suggested that UMIs
may not be associated with traditional CVD risk factors.7 Thus,
the identification of a cohort considered as low or intermediate
risk that have suffered from UMIs may provide insight into novel pre-
disposing aetiological factors.
The aim of this study was to investigate the prevalence of UMIs in
a large, non-high-risk, asymptomatic cohort, assessed with magnetic
resonance imaging (MRI), and the association between UMIs and
risk markers for CVD.
Methods
Study population
Following local ethics committee approval, a cohort of n ¼ 1651 volun-
teers were recruited to the imaging arm of the Tayside Screening for
Cardiovascular Events (TASCFORCE) study. Volunteers were recruited
to the study via general practitioner (GP) surgeries, advertising on radio
and via leaflets distributed at local public events and via large local em-
ployers. They were enrolled into TASCFORCE if they met the inclusion
criteria that they (i) were above the age of 40 years, (ii) were free from
CVD or other indication for statin therapy as recommended by the
Scottish Intercollegiate Guidelines Network (SIGN) report 97 (www.
sign.ac.uk) for ‘Risk Estimation and the Prevention of Cardiovascular
Disease’ published in February 2007, and (iii) had a 10-year risk of cor-
onary heart disease,20% as predicted by the Adult Treatment Panel III
(ATP-III) algorithm.8 Exclusion criteria included the following: (i) preg-
nancy; (ii) known primary muscle disease; (iii) known atherosclerotic
disease—including angina, previous myocardial infarction, peripheral ar-
terial disease, amputation, previous revascularization surgery, hyperten-
sion, heart failure, or cerebrovascular event; (iv) known diabetes; (v)
active liver disease; (vi) other known illness or contraindication to
MRI; (vii) participation in a clinical trial; (viii) inability to give informed
consent; (ix) known alcohol abuse; and (x) a blood pressure of
.145/95 mmHg. Participants who had a serum B-type natriuretic pep-
tide (BNP) level greater than their gender-specific median (7.5 pg/mL in
men, 15.3 pg/mL in women), indicating possible non-specific stress on
the cardiovascular system, were invited for whole-body MRI angiog-
raphy. Except for 14 men and 2 women, all participants had a BNP level
of ,100 pg/mL, which is the threshold used for the diagnosis of heart
failure, and therefore the vast majority of participants had a BNP in a
‘normal’ range. Of 1651 volunteers, 122 were excluded because of
claustrophobia or MR safety concerns, with 1529 (91.4%; 931 females
and 577 males, mean age 54 years, range 40–83 years) completing their
imaging.
Image acquisition
The MRI protocol has been described in detail elsewhere,9 but in brief,
imaging was performed using a 3 T Magnetom Trio Scanner (Siemens,
Erlangen, Germany). Whole-body MR angiography was performed
using a dual bolus injection technique with the CMR CINEs performed
before the first contrast injection and the LGE sequences performed be-
tween the first and second contrast bolus injections. For CMR, a body
matrix radiofrequency coil (6 elements) was used in combination with a
spine array (up to 24 elements).
ECG-gated, segmented, breath-hold, cinematic (CINE) TrueFISP
images were acquired from the atrioventricular ring to the LV apex
using 2D ECG-gated, breath-hold, segmented (CINE) TrueFISP se-
quence with retrospective gating. Retrospective ECG gating was
used, with 25 cardiac phases reconstructed (25 lines per segment)
and 2 image slices acquired per breath-hold. Parallel imaging was
also implemented [integrated parallel acquisition technique (iPAT)
×2], resulting in a scan time of ,15 s per breath-hold. An ECG-gated,
segmented, breath-hold, CINE 2D turbo Inversion Recovery ‘TI-scout’
sequence was implemented (in a central short-axis orientation) 8–
10 min after the injection of 10 mL of 0.5 mmol/mL gadoteric acid.
At a median of 11 min post-contrast (range 9–16 min), a short-axis
stack of ECG-gated, segmented, 2D phase-sensitive inversion recovery
images were acquired.10
Image analysis
LV mass and volume and whole-body atheroma burden quantification
were performed as previously described.9
Analysis of the LGE sequences was performed offline on a diagnostic
PACS radiological workstation (Kodak Carestream PACS Client Suite
Version 10.1 sp1, Rochester, NY, USA) by one of the two experienced
observers [one with 5 years (J.R.W.M.) and one with 15 years of experi-
ence (J.G.H.)] independently, with each scan being recorded as either
scar-positive or scar-negative. All positive scans were then classified
by consensus opinion with LGE classified as being sub-endocardial, mid-
myocardial, epicardial, or other. Thickness was scored as,50%,.50%,
or transmural. Sub-endocardial and transmural scarring were classed as
UMI. The location and extent were scored using the American Heart
Association (AHA) 17 segment model.11
The whole-body MRA analysis was performed as previously de-
scribed.9 In brief, the arterial tree was divided into 31 segments with
each scored according to the degree of narrowing of the lumen diam-
eter, with stenosis graded at the narrowest part of the vessel. Each ves-
sel was scored from 0 to 4, where 0, segment with no stenosis; 1, ,50%
stenosis; 2, 51–70% stenosis; 3, 71–99% stenosis; and 4, vessel occlu-
sion. The ‘standardized atheroma score’ (SAS) was calculated by sum-
ming each individual segment’s stenosis score and divided by the
number of diagnostic segments (n) before dividing by 4 that is the max-
imum potential score [Eq. (1)]:
SAS = SMRA score/n
4
[ ]
× 100 (1)
Statistical analysis
Data are expressed as mean+ standard deviation (SD) for normally dis-
tributed continuous variables, median (range) for non-normally distrib-
uted continuous and ordinal variables, and n (%) for nominal variables.
To test the null hypothesis that samples originate from the same distri-
bution, an independent sample Kruskal–Wallis test was used, with post
hoc Mann–Whitney U test to further evaluate between group differ-
ences when a significant difference was observed from the Kruskal–
Wallis test. Fisher’s exact test was used to compare nominal data. All
J.R. Weir-McCall et al.Page 2 of 6
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data were analysed using SPSS statistical package (version 21.0, IBM
SPSS, Chicago, IL, USA). Significance was assumed when P, 0.05.
Results
Fifty-three of the 1529 (3.6%) CMRs were excluded because of ei-
ther missing data or inadequate LGE image quality. Ten of the re-
maining 1476 (0.67%) displayed delayed myocardial enhancement,
of which 90% were female (age 54+ 8 years). Of these, three
(0.2%) demonstrated sub-endocardial enhancement in a pattern
consistent with UMIs. Of these three,
(i) one involved eight AHA segments in the left anterior descend-
ing (LAD) territory, with full thickness involvement of the ap-
ical segments and ,50% thickness involvement in the
mid-cavity segments, and an ejection fraction of 36.3%;
(ii) the second involved six segments in the LAD territory, with full
thickness involvement of the apical segments and ,50% thick-
ness involvement in the mid-cavity segments, associated with
regional hypokinesia, but a preserved ejection fraction of 55%;
(iii) the final infarct involved two segments in the inferolateral wall
basally, with ,50% myocardial thickness scarring, associated
with regional wall motion abnormality but a preserved ejection
fraction (see Figure 1).
Of the remaining seven (0.47%),
(i) one demonstrated epicardial enhancement involving one AHA
segment;
(ii) four had a mid-myocardial pattern of enhancement, all four of
which involved a single AHA segment;
(iii) two had right ventricular septal insertion point enhancement
each involving one AHA segment.
None of these were associated with regional wall motion
abnormalities.
Of the three patients with UMI pattern LGE, only one had clinical
symptoms describing shortness of breath on exertion, which had
been labelled by their GP as chronic obstructive pulmonary disease
because of a history of smoking and an obstructive pattern on spir-
ometry, but on review was felt to more likely be owing to their
systolic impairment. Single-photon emission computed tomography
(SPECT) study confirmed a large irreversible perfusion defect in the
LAD territory. Neither of the other two with UMI exhibited any
chest pain or shortness of breath. Those with atypical LGE patterns
were asymptomatic, with no prior recalled episodes of significant
chest pain.
The demographic data are described in Table 1. Those with UMIs
had a significantly higher BNP [116 (31–133) vs. 22.6 (5–175) pg/
mL, P ¼ 0.015] compared with the group without the evidence of
LGE but were otherwise similar in their baseline measures. Those
with non-specific scarring had lower diastolic blood pressure [68
(54–70) vs. 72 (46–98) mmHg, P ¼ 0.013], but were otherwise
similar to those without scarring. Imaging findings of the two groups
are described in Table 2. Compared with those without scarring,
those with UMIs had significantly lower ejection fractions [54.6
(36–62) vs. 68.9 (38–89)%, P ¼ 0.007] and higher end-systolic vo-
lumes [36.3 (27–61) vs. 21.7 (5–65) mL/m2, P ¼ 0.014], whereas
those with non-specific LGE demonstrated no significant differences
in cardiac mass, volume, or function. Neither group demonstrated a
significantly higher atheroma burden than those with no scarring
(P ¼ 0.27).
Discussion
In this study, we have demonstrated that those who are of middle-
age with an intermediate or low cardiovascular risk have a very low
risk of UMIs. The prevalence of UMIs of 0.2% in our study is similar
to the 0.34% reported by Goehde et al.,12 although this prior study
had focused on a younger age group than the current study with a
mean age of 49.7 compared with our 54.2 years, 15.8% of their
population being under 40 with under 40s excluded from recruit-
ment within our study and finally only 2.6% of their population
were over 65 compared with our 10.5%. This is important as two
prior studies focusing on 70- and 75-year-olds, respectively, de-
scribed a prevalence of 19.8% in the 70-year-old cohort and 30%
in the 75-year-olds, consistent with a strong age-related associ-
ation.4,13 The same group also demonstrated a lack of association
between the presence of UMIs and traditional risk factors, carotid
intima media thickness, high-sensitivity C-reactive protein, or
Figure 1 Examples of myocardial enhancement patterns observed. (A) Sub-endocardial enhancement in the inferolateral wall of the basal left
ventricle consistent with a myocardial infarct. (B) Mid-myocardial enhancement. (C) RV insertion point enhancement.
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whole-body atheroma burden.7 Although the average age of our
study was significantly lower than that observed in these two prior
studies, there were 331 participants over 60 years of age and 63
over the age of 70; thus, a significantly higher incidence of UMI
would have been expected in our cohort on the basis of these prior
studies. This suggests that the lack of observed differences between
the population with and without UMI in these previous studies may
have simply been due to being underpowered to detect differences,
because when we have excluded those considered at high risk of
CVD (calculated using standard risk factor measurements), the
prevalence of UMIs is vanishingly low. A previous study by Schelbert
et al. reported an incidence of UMIs of 17%, but this was again a
much older population, including high-risk participants and those
with known coronary artery disease.6 Contrary to Barbier’s work
and supported by our own study, they found a significantly greater
prevalence of traditional CVD risk factors in those with UMIs com-
pared with those without. They also found the incidence to be sig-
nificantly higher in those with diabetes. Indeed, in comparison to our
current study, a healthy population with diabetes and similar demo-
graphic characteristics as our group demonstrated a prevalence of
6% UMIs.14
Knowledge of the prevalence and population likely to have UMIs
is important for several reasons. First and most importantly is their
significant prognostic implications, with those with UMIs at marked-
ly increased risk of future cardiovascular events.1,6 Indeed in our
study, UMIs had significant functional implications, with these asso-
ciated with reduced ejection fraction, dilation of the LV cavity, and
an elevated BNP. Those with UMIs have been shown to have a high
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Comparison of cohort characteristics between those with and without late gadolinium enhancement
No LGE UMI Non-specific LGE P
n (%) 1463 (99.1) 3 (0.2) 7 (0.5)
Male (%) 561 (38) 0 (0) 1 (14) 0.26
Age (years) 53.4 (40–80) 62 (53–66) 58.1 (50–67) 0.13
Pulse 62 (35–92) 67 (61–82) 62 (54–70) 0.44
Systolic BP 122 (80–145) 118 (104–134) 128 (102–140) 0.71
Diastolic BP 72 (46–98) 64 (58–76) 68 (58–70) 0.018
Total cholesterol 5.4 (2.7–9.5) 5.4 (5.2–6.4) 5.4 (4.6–7.2) 0.87
LDL-cholesterol (mmol/L) 3.4 (0.9–6.8) 3.3 (3.2–3.9) 3.2 (2.3–4.7) 0.96
HDL-cholesterol (mmol/L) 1.4 (0.4–2.6) 1.8 (1.3–1.8) 1.5 (0.9–2.3) 0.94
Triglycerides (mmol/L) 1.3 (0.5–7) 1.6 (0.5–1.7) 1.1 (0.5–2.5) 0.37
Random glucose 5.1 (3–11) 5.3 (5–6) 6.2 (5–8) 0.11
ASSIGN risk score 7.4 (0.9–48) 10.3 (10–13) 6 (3–17) 0.46
BMI (kg/m2) 26.1 (17–43) 27.6 (25–29) 22.9 (21–31) 0.09
Current/ex-smoker (%) 552 (38) 1 (33) 3 (43) 1
Smoking pack years 0 (0–105) 0 (0–30) 0 (0–57) 0.91
FH of CVD (%) 377 (26) 1 (33) 0 (0) 0.2
BNP (pg/mL) 22.7 (5–175) 116 (31–133) 22.6 (10–62) 0.05
ASSIGN, ASsessing cardiovascular risk using SIGN guidelines; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; CVD, cardiovascular disease; FH, family
history; HDL, high density lipoprotein; LDL, low density lipoprotein; LGE, late gadolinium enhancement; UMI, unrecognized myocardial infarction.
Bold indicates statistical significance.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Comparison of left ventricular measures and whole-body atheroma burden between the groups
No LGE UMI Non-specific LGE P
LVMa (g/m2) 53.6 (26–109) 64.1 (59–67) 47.7 (40–60) 0.08
LVEDVa (mL/m2) 70.5 (38–140) 79.9 (72–96) 69.6 (61–81) 0.23
LVESVa (mL/m2) 21.7 (5–66) 36.3 (27–61) 19.9 (13–28) 0.033
LVSVa (mL/m2) 48.3 (24–92) 43.7 (35–45) 49.7 (40–54) 0.20
LVEF (%) 68.9 (38–89) 54.7 (36–62) 71.4 (65–78) 0.019
LVMVR (g/mL) 0.76 (0.4–2.1) 0.74 (0.7–0.9) 0.70 (0.6–0.8) 0.30
SAS 0 (0–19.6) 4.2 (0–9) 0 (0–2) 0.27
LGE, late gadolinium enhancement; LVM, left ventricular mass; EDV, end diastolic volume; ESV, end-systolic volume; EF, ejection fraction; SV, stroke volume; LVMVR, left ventricular
mass volume ratio; SAS, standardized atheroma score; UMI, unrecognized myocardial infarction.
aNormalized to body surface area.
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prevalence of significant coronary stenosis, both globally within the
coronary vessels and focally upstream from the lesion, particularly in
UMIs occurring in the LAD territory.15,16 There are promising data
showing the benefits of intervening in silent ischaemia,17 thus this
population may benefit from more aggressive management. How-
ever, prior studies have focused on SPECT assessment, and thus fur-
ther work on those with asymptomatic UMIs recognized by CMR is
still required. Second, if a high prevalence of UMIs was to be ob-
served in a young cohort, it would suggest significant missed oppor-
tunity for primary prevention. Our finding of a very low rate of UMIs
in a predominantly middle-aged population without the high risk of
CVD provides reassurance that this is not the case and that preven-
tion efforts need not occur at excessively young ages, instead being
better focused on middle and older ages.18
More prevalent than UMIs in our current cohort, but still uncom-
mon affecting only 0.47% of the group, was LGE in a pattern not typ-
ical of myocardial infarction. The most common of these was
mid-myocardial enhancement, which is non-specific and can be
seen in hypertensive cardiomyopathy, infiltrative cardiomyopathies,
and myocarditis.19 Given that those with high blood pressure were
excluded from the study and that the LV mass was not significantly
elevated in these cases, the former two are less likely, leaving prior
undiagnosed myocarditis as a possible source of this myocardial en-
hancement. In these participants with possible subclinical events, the
lack of difference in ventricular function or volumes is reassuring
that there do not appear to be any significant downstream sequelae
of these scars. This is in agreement with recent work showing the
lack of significant impact on prognosis between those with and with-
out LGE in patients with clinically apparent myocarditis.20,21 The
finding of a lower diastolic blood pressure in the cohort with non-
specific LGE compared with the cohort without any LGE is uncer-
tain but may be a manifestation of the high prevalence of females in
the non-specific group, or possibly erroneous because of the small
group size.
There are several weaknesses in the current study. We acquired
the LGE following a single-dose contrast injection, whereas clinical
routine practice is for this to be performed following double dose.
However, at 3 T, contrast exerts a greater effect on T1 relaxation,
and single-dose LGE has been proved to be equivalent with double
dose imaging for scar detection.22 Our LGE imaging was acquired
only in the short-axis plane, thus apical lesions that are better appre-
ciated on long-axis views may have been missed, although previous
reports have shown this to be an uncommon location for UMIs.4 In
addition, the lack of a second plane for correlation may have led to
under-reporting of areas of indeterminate signal, potentially under-
estimating the true prevalence. The numbers of both the UMIs and
non-specific LGE were small meaning only limited conclusions can
be drawn from inter-group data comparison. Additionally, this
was a single-centre study on a predominantly white population,
thereby limiting the generalizability of our findings to other groups.
Participants were recruited based on an old threshold for the diag-
nosis of hypertension (145/90 mmHg) and using the ATP-III criteria,
both of which were the reference standard at the point of study de-
sign, but have been superseded by more up-to-date risk criteria.
Thus, our healthy cohort included some participants with what
would now be considered hypertension. However, this would be
expected to bias the results in favour of a higher rate of UMIs;
thus, our findings of a low prevalence in this cohort remain valid.
For the purposes of this paper for comparing risk between cohorts,
we have instead adopted the ASSIGN score, as this has the greatest
evidence basis in a Scottish cohort.23
Conclusion
Despite previous reports describing high prevalence of UMI in older
populations, in a predominantly middle-aged cohort, those who are
of intermediate or low cardiovascular risk have a very low risk of
having an UMI.
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